Overview

Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

Status:
Recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants.
Phase:
Phase 2
Details
Lead Sponsor:
Darcy Krueger
Collaborator:
Food and Drug Administration (FDA)
Treatments:
Sirolimus